Biogen (NASDAQ:BIIB) Price Target Raised to $187.00

Biogen (NASDAQ:BIIB) had its price target raised by Wedbush from $178.00 to $187.00 in a research note released on Monday morning, MarketBeat reports. They currently have a neutral rating on the biotechnology company’s stock.

Several other brokerages also recently commented on BIIB. Citigroup increased their target price on shares of Biogen from $180.00 to $185.00 and gave the company a “neutral” rating in a report on Tuesday, January 27th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Biogen in a research note on Monday, December 29th. HC Wainwright boosted their price objective on Biogen from $194.00 to $228.00 and gave the stock a “buy” rating in a research note on Monday. Stifel Nicolaus increased their target price on shares of Biogen from $202.00 to $214.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Finally, Wall Street Zen cut shares of Biogen from a “buy” rating to a “hold” rating in a report on Sunday, November 9th. Thirteen analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $206.54.

Biogen Trading Up 1.2%

BIIB stock opened at $191.20 on Monday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. Biogen has a 52 week low of $110.04 and a 52 week high of $202.41. The company has a market capitalization of $28.06 billion, a PE ratio of 21.70, a price-to-earnings-growth ratio of 1.50 and a beta of 0.16. The company’s 50-day simple moving average is $177.65 and its 200 day simple moving average is $158.12.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the prior year, the firm posted $3.44 EPS. The firm’s quarterly revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, sell-side analysts anticipate that Biogen will post 15.83 earnings per share for the current year.

Insider Buying and Selling at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the sale, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.18% of the company’s stock.

Institutional Trading of Biogen

Several large investors have recently modified their holdings of BIIB. Privium Fund Management B.V. bought a new stake in shares of Biogen during the second quarter valued at about $2,666,000. Nordea Investment Management AB lifted its holdings in shares of Biogen by 5.7% during the second quarter. Nordea Investment Management AB now owns 125,935 shares of the biotechnology company’s stock worth $15,810,000 after buying an additional 6,811 shares during the last quarter. Convergence Investment Partners LLC bought a new stake in shares of Biogen during the third quarter valued at approximately $1,342,000. Pitcairn Co. bought a new position in shares of Biogen during the 2nd quarter worth approximately $936,000. Finally, Fluent Financial LLC bought a new stake in shares of Biogen during the third quarter worth $3,578,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat FY‑2026 guidance — Biogen reported Q4 results that topped EPS and revenue expectations and provided FY‑2026 EPS guidance (15.25–16.25) that reassured investors about earnings power. This is a primary driver of recent price strength. Why Biogen Is Up After Earnings
• Positive Sentiment: Analyst upgrades and higher price targets — Several firms raised targets and reiterated buys after the results (examples: Mizuho, Goldman Sachs, Canaccord, Citigroup and others), supporting further upside sentiment. Mizuho Raises Price Target
• Positive Sentiment: Regulatory progress for Leqembi (lecanemab) — The BLA for a subcutaneous formulation of Leqembi received priority review, which could expand commercial reach and margins if approved. That helped sentiment around Biogen’s Alzheimer’s growth runway. Leqembi Subcutaneous Priority Review
• Neutral Sentiment: Board leadership change — Caroline Dorsa is retiring as Board Chair; Dr. Maria C. Freire was elected Chair effective immediately. Governance continuity reduces uncertainty but is unlikely to be a major near‑term price mover. Board Chair Transition
• Neutral Sentiment: Pipeline diversification updates — Advances in lupus and SMA programs improve long‑term optionality but will take time to drive revenue; these were noted by coverage but are not immediate catalysts. Pipeline Advances
• Neutral Sentiment: Short‑interest data appears inconsistent — Recent feeds reporting a “significant increase” actually show zero shares, so no clear short‑squeeze dynamics are evident from the available data. (internal short‑interest entries)
• Negative Sentiment: Insider selling — Senior insider Priya Singhal sold 2,660 shares (~$531k), which some investors interpret as a modest negative signal about near‑term insider conviction. Insider Form 4
• Negative Sentiment: Legacy franchise pressure and execution risks — Analysts caution that MS franchise erosion and the challenges of scaling Leqembi access/commercialization could limit upside and add execution risk. Franchise Pressure Analysis

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.